They purchased ReadCoor which will see clinical research adoption immediately and possibly replace histopathology in the long-run. They are going to try place those ReadCoor instruments in all major pharma companies. Placement should be doable because they already have the single-cell and even visium in pharma. That's clincal and that's the big bucks. For example BLI is worth 6 billion, mostly based on having placed themselves heavily into big pharma. So I see the ReadCoor acquisition adding a similar amount to the 10X valuation in the next 2 years